Genta to Present at JP Morgan Healthcare Conference
Thursday January 8, 8:00 am ET
BERKELEY HEIGHTS, N.J., Jan. 8 /PRNewswire-FirstCall/ -- Genta Incorporated (Nasdaq: GNTA - News) announced that it will present at the JP Morgan Healthcare Conference in San Francisco, CA. Dr. Raymond P. Warrell, Jr., Genta's Chief Executive Officer, will provide an update on the Company's products and development programs on Thursday, January 15, 2004 at 12:00 noon EST.
ADVERTISEMENT
A live audio webcast of the presentation can be accessed through Genta's Investor Relations site at: genta.com. A replay will be available approximately 24 hours following the presentation and will be available for 30 days thereafter.
About Genta
Genta Incorporated is a biopharmaceutical company with a diversified product portfolio that is focused on delivering innovative products for the treatment of patients with cancer. The Company's research platform is anchored by two major programs that center on oligonucleotides (RNA and DNA-based medicines) and small molecules. Genasense(TM) (oblimersen sodium), the Company's lead compound from its oligonucleotide program, is being developed with Aventis and is currently undergoing late-stage, Phase 3 clinical testing. The leading drug in Genta's small molecule program is Ganite(TM) (gallium nitrate injection), which the Company is exclusively marketing in the U.S. for treatment of patients with cancer-related hypercalcemia that is resistant to hydration. For more information about Genta, please visit our website at: www.genta.com. |
